RareCyte® announces the CyteFinder® II and CyteFinder II HT Instruments in conjunction with the American Association for Cancer Research Annual Meeting in AtlantaSeattle, WA, March 28, 2019 – RareCyte® announces the CyteFinder® II and CyteFinder II HT Instruments in conjunction with the American Association for Cancer Research Annual Meeting in Atlanta, March 29 through April 3. These next generation CyteFinder Instruments expand on RareCyte’s world class liquid biopsy platform to support tissue workflows. Both instruments perform rapid, whole slide imaging in seven fluorescence channels as well as brightfield for IF, IHC, and H&E samples and are designed for placement in clinical laboratories. Together, the CyteFinder II systems provide one platform for fast, multiplexed imaging with multi-omic results.
RareCyte expands liquid biopsy offerings with the RarePlex™ CTC Developer Kit for custom biomarkers, and introduces the next generation CytePicker® Cell Retrieval Module for single cell and tissue micro-region retrieval
Seattle, WA, March 11, 2019 – RareCyte, Inc., a global rare cell detection and liquid biopsy company, announces its newest products, the RarePlex™ CTC Developer Kit, and the next generation CytePicker® Cell Retrieval Module in conjunction with the Molecular Med Tricon Meeting in San Francisco March 10 through 15. The RarePlex CTC Developer Kit leverages the robust detection and enumeration of circulating tumor cells (CTCs) of the RareCyte base CTC detection assay and enables characterization of those CTCs with up to two custom biomarkers. This capability enables customers to independently innovate and create a wide range of CTC detection assays utilizing biomarkers of interest and expand on the RareCyte liquid biopsy platform.
RareCyte Completes $30M Private Financing for Commercial Expansion of Rare Cell Detection Technology for Liquid BiopsiesSeattle, WA, August 24, 2017 – RareCyte, Inc., a global rare cell detection and liquid biopsy company will use the funding to advance its commercial sales efforts and build companion diagnostics (CDx) programs with strategic partners. The company will also expand its regulatory infrastructure and research and development efforts. The $30M investment was led by 5AM Ventures with participation from existing investors Telegraph Hill Partners (THP), founder Ron Seubert and other investors.
RareCyte introduces the CyteFinder® HT instrument at AACR for high throughput slide-based imaging optimized for single cell Liquid BiopsySeattle, WA, April 16, 2018 – RareCyte, Inc., a global rare cell detection and liquid biopsy company announces its newest product, CyteFinder HT in conjunction with the American Association for Cancer Research (AACR) Annual Meeting in Chicago April 15 through 18. CyteFinder HT, RareCyte’s newest member of the CyteFinder family enables high-speed whole slide imaging with up to six channels specifically designed for the needs of high throughput liquid biopsy applications. The CyteFinder HT incorporates slide cassettes for unattended imaging of up to 80 slides and enables processing of up to 120 slides in 24 hours for cells, blood smears, or tissue samples.
Next Generation Dx Summit
20-22 August 2019
Grand Hyatt Washington
Booth # 117
Advances in CTCs
02-05 October 2019
Corfu Holiday Palace Conference Center
2019 NCRI Cancer Conference
03-05 November 2019
Scottish Event Campus
Society for Immunotherapy of Cancer
06-10 November 2019
Gaylord National Hotel
National Harbor, MD
Association for Molecular Pathology
07-09 November 2019
Baltimore Convention Center